Skip to content
The Nexus
DossierENTITY

GIPR

Coverage of GIPR in the Nexus archive.

Earliest in view: Apr 8 · 00:00 UTCMost recent: Apr 29 · 00:00 UTC
Co-mentioned in this coverage
Natureorganization2GLP-1–GIP–lanifibranortopic1GLP-1Rtopic1PPARαtopic1PPARγtopic1PPARδtopic1obesity-linked metabolic dysfunctiontopic1GLP1Rtopic1GLP-1topic1
Recent coverage
  • HEALTHApr 29 · 00:00 UTCNATURE NEWS
    GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice

    A single-molecule agonist targeting GLP-1R, GIPR, and PPARα/γ/δ receptors (GLP-1–GIP–lanifibranor) demonstrates therapeutic efficacy in correcting obesity and diabetes in mouse models through synergistic metabolic pathways. Published in Nature, the study highlights its potential for treating obesity-linked metabolic dysfunction.

  • HEALTHApr 8 · 00:00 UTCNATURE NEWS
    Genetics reveal why people respond differently to GLP-1 weight-loss drugs

    A study published in Nature identifies genetic variants in GLP1R and GIPR genes as key factors influencing individual responses to GLP-1-based weight-loss drugs. These variants may explain varying drug effectiveness and potential adverse effects among patients.